Re: Safety and Efficacy of Durvalumab (MEDI4736), an Anti-Programmed Cell Death Ligand-1 Immune Checkpoint Inhibitor, in Patients with Advanced Urothelial Bladder Cancer

被引：5
|
作者：
Chang, Sam S.
机构：
来源：
JOURNAL OF UROLOGY | 2018年 / 199卷 / 02期
关键词：
D O I：
10.1016/j.juro.2017.11.024
中图分类号：
R5 [内科学]; R69 [泌尿科学（泌尿生殖系疾病）];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：341 / 342
页数：2
相关论文
共 50 条
  • [41] A phase II study to evaluate the efficacy and safety of combination therapy of durvalumab (MEDI4736) and amrubicin in patients with recurrent small cell lung cancer (SCLC): Aphrodite trial, in progress.
    Kato, Yuka
    Ohashi, Kadoaki
    Kozuki, Toshiyuki
    Kuyama, Shoichi
    Yamaguchi, Kakuhiro
    Yokoyama, Toshihide
    Uno, Hideki
    Yoshida, Michihiro
    Hattori, Noboru
    Hotta, Katsuyuki
    Kiura, Katsuyuki
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [42] A Phase Ib Study of Durvalumab (MEDI4736) in Combination with Carbon-Ion Radiotherapy and Weekly Cisplatin for Patients with Locally Advanced Cervical Cancer (DECISION Study): The Early Safety and Efficacy Results
    Okonogi, Noriyuki
    Murata, Kazutoshi
    Yamada, Shigeru
    Habu, Yuji
    Hori, Makoto
    Kurokawa, Tomoya
    Inaba, Yosuke
    Fujiwara, Tadami
    Fujii, Yasuhisa
    Hanawa, Michiko
    Kawasaki, Yohei
    Hattori, Yoko
    Suzuki, Kazuko
    Tsuyuki, Kyoko
    Wakatsuki, Masaru
    Koto, Masashi
    Hasegawa, Sumitaka
    Ishikawa, Hitoshi
    Hanaoka, Hideki
    Shozu, Makio
    Tsuji, Hiroshi
    Usui, Hirokazu
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2023, 24 (13)
  • [43] Risk of fatigue in cancer patients treated with anti programmed cell death-1/anti programmed cell death ligand-1 agents: a systematic review and meta-analysis
    Santoni, Matteo
    Conti, Alessandro
    Buti, Sebastiano
    Bersanelli, Melissa
    Foghini, Laura
    Piva, Francesco
    Giulietti, Matteo
    Lusuardi, Lukas
    Battelli, Nicola
    IMMUNOTHERAPY, 2018, 10 (15) : 1303 - 1314
  • [44] Prevalence of immune-related systemic adverse events in patients treated with anti-Programmed cell Death 1/anti-Programmed cell Death-Ligand 1 agents: A single-centre pharmacovigilance database analysis
    Le Burel, Sebastien
    Champiat, Stephane
    Mateus, Christine
    Marabelle, Aurelien
    Michot, Jean-Marie
    Robert, Caroline
    Belkhir, Rakiba
    Soria, Jean-Charles
    Laghouati, Salim
    Voisin, Anne-Laure
    Fain, Olivier
    Mekinian, Arsene
    Coutte, Laetitia
    Szwebel, Tali-Anne
    Dunogeant, Laetitia
    Lioger, Bertrand
    Luxembourger, Cecile
    Mariette, Xavier
    Lambotte, Olivier
    EUROPEAN JOURNAL OF CANCER, 2017, 82 : 34 - 44
  • [45] Safety and efficacy of anti-programmed death 1 antibodies in patients with cancer and pre-existing autoimmune or inflammatory disease
    Danlos, Francois-Xavier
    Voisin, Anne-Laure
    Dyevre, Valerie
    Michot, Jean-Marie
    Routier, Emilie
    Taillade, Laurent
    Champiat, Stephane
    Aspeslagh, Sandrine
    Haroche, Julien
    Albiges, Laurence
    Massard, Christophe
    Girard, Nicolas
    Dalle, Stephane
    Besse, Benjamin
    Laghouati, Salim
    Soria, Jean-Charles
    Mateus, Christine
    Robert, Caroline
    Lanoy, Emilie
    Marabelle, Aurelien
    Lambotte, Olivier
    EUROPEAN JOURNAL OF CANCER, 2018, 91 : 21 - 29
  • [46] Efficacy and safety profiles of programmed cell death-1/programmed cell death ligand-1 inhibitors in the treatment of triple-negative breast cancer: A comprehensive systematic review
    Lazarus, Gilbert
    Audrey, Jessica
    Iskandar, Anthony William Brian
    ONCOLOGY REVIEWS, 2019, 13 (02) : 161 - 169
  • [47] Prognostic value of programmed cell death ligand-1 expression in patients with bladder urothelial carcinoma undergoing radical cystectomy: A meta-analysis
    Zhang, Jindong
    Song, Liangdong
    Zhu, Huixuan
    Liu, Qinyuan
    Wang, Delin
    FRONTIERS IN IMMUNOLOGY, 2022, 13
  • [48] Hyperprogression after anti-programmed cell death ligand-1 therapy in a patient with recurrent metastatic urothelial bladder carcinoma following first-line cisplatin-based chemotherapy: a case report
    Mao, Shiyu
    Zhang, Junfeng
    Guo, Yadong
    Zhang, Ziwei
    Wu, Yuan
    Zhang, Wentao
    Wang, Longsheng
    Geng, Jiang
    Yan, Yang
    Yao, Xudong
    DRUG DESIGN DEVELOPMENT AND THERAPY, 2019, 13 : 291 - 300
  • [49] Phase Ib study of MEDI4736, a programmed cell death ligand-1 (PD-L1) antibody, in combination with tremelimumab, a cytotoxic T-lymphocyte-associated protein-4 (CTLA-4) antibody, in patients (pts) with advanced NSCLC.
    Antonia, Scott Joseph
    Goldberg, Sarah B.
    Balmanoukian, Ani Sarkis
    Sanborn, Rachel E.
    Steele, Keith
    Narwal, Rajesh
    Robbins, Paul B.
    Gu, Yu
    Karakunnel, Joyson Joseph
    Rizvi, Naiyer A.
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [50] Significance of functional soluble programmed cell death ligand-1 (sPD-L1) in blood of advanced cancer patients
    Homma, Sadamu
    Ito, Masaki
    Sagawa, Yukiko
    Kamata, Yuko
    Koido, Shigeo
    CANCER SCIENCE, 2018, 109 : 98 - 98
12345